Autolus Raises Sales Outlook as AUCATZYL Growth Accelerates
The cell-therapy developer reported preliminary AUCATZYL net product revenue of approximately $45 million for the second quarter.
Autolus Therapeutics (AUTL) said second-quarter AUCATZYL sales rose about 70% sequentially as use expanded within existing treatment centers and additional sites came online.
The increase marked a sharp acceleration for the cell-therapy developer. AUCATZYL revenue had risen from $23.3 million in the fourth quarter of 2025 to $26.2 million in the first quarter of 2026 before climbing again in the latest period.
Preliminary net product revenue more than doubled from the second quarter of 2025. Growth is attributed to broader use at authorized treatment centers and the addition of new centers, following first-quarter momentum from U.S. market-share expansion and the January launch in the U.K.
Higher product volumes also helped lift gross margin to approximately positive 35% in the first half of 2026 from approximately negative 20% in the second half of 2025. Operating-efficiency initiatives contributed to the improvement.
Autolus now expects full-year 2026 AUCATZYL sales of $140 million to $150 million, up from its previous forecast of $120 million to $135 million. The revision raised the bottom of the range by $20 million and the top by $15 million.
The company also secured a five-year, interest-only senior credit facility of up to $250 million. Autolus received $75 million at closing, can draw another $25 million during the following six months, and may access as much as $150 million more upon meeting revenue milestones.
The first two potential tranches, totaling $100 million, together with existing cash and securities, are expected to fund operations into the second quarter of 2028.